RECURRENT GLIOBLASTOMA MULTIFORME: IMPLICATION OF NONENHANCING LESIONS ON BEVACIZUMAB TREATMENT

被引：0
|
作者：
Alexandru, Daniela [1 ]
Bota, Daniela [1 ]
Linskey, Mark E. [1 ]
机构：
[1] UCI Med Ctr, Orange, CA USA
来源：
NEURO-ONCOLOGY | 2011年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [1] Bevacizumab: A treatment option for recurrent glioblastoma multiforme
    Buie, Larry W.
    Valgus, John M.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (10) : 1486 - 1490
  • [2] Bevacizumab in recurrent glioblastoma multiforme
    Tayah, Tania
    Ashrafieh
    Chahine, Georges Y.
    Kamar, Francois G.
    NEUROLOGY, 2008, 70 (11) : A296 - A297
  • [3] Irinotecan and bevacizumab in recurrent glioblastoma multiforme
    Jakobsen, Jan Nyrop
    Hasselbalch, Benedikte
    Stockhausen, Marie-Therese
    Lassen, Ulrik
    Poulsen, Hans Skovgaard
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (05) : 825 - 833
  • [4] Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
    Francesconi, Alessandra B.
    Dupre, Simon
    Matos, Marco
    Martin, David
    Hughes, Brett G.
    Wyld, David K.
    Lickliter, Jason D.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2010, 17 (08) : 970 - 974
  • [5] Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme
    Cabrera, Alvin R.
    Cuneo, Kyle C.
    Vredenburgh, James J.
    Sampson, John H.
    Kirkpatrick, John P.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (06): : 695 - 699
  • [6] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    Vredenburgh, James J.
    Desjardins, Annick
    Herndon, James E., II
    Marcello, Jennifer
    Reardon, David A.
    Quinn, Jennifer A.
    Rich, Jeremy N.
    Sathornsumetee, Sith
    Gururangan, Sridharan
    Sampson, John
    Wagner, Melissa
    Bailey, Leighann
    Bigner, Darell D.
    Friedman, Allan H.
    Friedman, Henry S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4722 - 4729
  • [7] Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
    Pope, Whitney B.
    Kim, Hyun J.
    Huo, Jing
    Alger, Jeffry
    Brown, Matthew S.
    Gjertson, David
    Sai, Victor
    Young, Jonathan R.
    Tekchandani, Leena
    Cloughesy, Timothy
    Mischel, Paul S.
    Lai, Albert
    Nghiemphu, Phioanh
    Rahmanuddin, Syed
    Goldin, Jonathan
    RADIOLOGY, 2009, 252 (01) : 182 - 189
  • [8] FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
    Cohen, Martin H.
    Shen, Yuan Li
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2009, 14 (11): : 1131 - 1138
  • [9] Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
    Schiff, David
    Purow, Benjamin
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (04): : 186 - 187
  • [10] Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis
    Wong, Eric T.
    Gautam, Shiva
    Malchow, Christopher
    Lun, Melody
    Pan, Edward
    Brem, Steven
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (04): : 403 - 407
12345